Skip to main content

Table 1 Risk factors and clinical characteristics of the study population

From: Budd-Chiari syndrome: epidemiological and clinical characteristics of a case series in Northwest Spain

Total number of patients 15
 Sex, male, n (%) 8 (53.3%)
 Age in years, median (IQR) 52 (39–75)
Active cancer,n(%) 6 (40.0%)
 Colorectal cancer, n (%) 2 (13.3%)
 Haematological malignancy, n (%) 2 (13.3%)
 Hepatocarcinoma, n (%) 1 (6.7%)
 Ovarian cancer, n (%) 1 (6.7%)
 Liver abscess, n (%) 4 (26.7%)
 Prior cirrhosis diagnosis, n (%) 2 (13.3%)
 Paroxysmal nocturnal haemoglobinuria 1 (6.7%)
 Factor V Leiden mutation, n (%) 1 (6.7%)
 Antiphospholipid syndrome 1 (6.7%)
Clinical debut
 Acute hepatitis, n (%) 5 (33.3%)
 Subacute hepatitis, n (%) 8 (53.3%)
 Liver cirrhosis, n (%) 2 (13.3%)
Laboratory parameters at diagnosis
 Haemoglobin (g/dL), median (IQR) 11.6 (9.7–13.5)
 Platelets (×109/L), median (IQR) 194 (105–226)
 International normalised ratio 1.2 (1.1–1.4)
 Fibrinogen (mg/dL), median (IQR) 438.5 (331.0–578.0)
 Alanine aminotransferase, ALT, (UI/L), median (IQR) 38 (30.3–78.8)
 Aspartate aminotransferase, AST (UI/L), median (IQR) 46 (32.0–85.0)
 Albumin (mg/dL), median (IQR) 3.0 (2.7–3.6)
 Total bilirubin (mg/dL), median (IQR) 1.1 (0.6–2.0)
Diagnostic test performed
 CT 12 (80.0%)
 US-Doppler 5 (33.3%)
 MRI 4 (26.7%)
Anatomic location
 Right suprahepatic vein 4 (26.7%)
 Left, middle, and right suprahepatic veins 4 (26.7%)
 Middle suprahepatic vein 2 (13.3%)
 Middle and right suprahepatic veins 2 (13.3%)
 Middle and left suprahepatic veins 2 (13.3%)
 Left suprahepatic vein 1 (6.7%)
  1. IQR, inter-quartile range; CT, computerised tomography; US-Doppler, Doppler ultrasound; MRI, magnetic resonance imaging